SCHEMBL2117754

SCHEMBL2117754

O/N=C/c1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP1A2 P05177 1/20 0.48
PTGS1 P23219 2/20 0.47
KMT2A Q03164 1/20 0.47
NQO2 P16083 1/20 0.46
PTGS2 P35354 2/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
HDAC3 O15379 1/20 0.44
ADAM17 P78536 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
AHR P35869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117755 1.00 LMNA (0.53) LMNAALDH1A1CYP1A2PTGS1KMT2A
SCHEMBL2165990 1.00 LMNA (0.53) LMNAALDH1A1CYP1A2PTGS1KMT2A
Hydrochloric Acid SCHEMBL28409325 0.98 LMNA (0.51) LMNAALDH1A1CYP1A2PTGS1KMT2A
SCHEMBL2910604 0.90 LMNA (0.46) LMNAALDH1A1CYP1A2PTGS1KMT2A
SCHEMBL2910600 0.90 LMNA (0.46) LMNAALDH1A1CYP1A2PTGS1KMT2A
SCHEMBL13798820 0.80 TRPV1 (0.61) LMNAALDH1A1PTGS1KMT2AHDAC3
SCHEMBL4275683 0.80 KMT2A (0.64) ALDH1A1KMT2ASMN1; SMN2KDM4EGAA
SCHEMBL4275687 0.80 KMT2A (0.64) ALDH1A1KMT2ASMN1; SMN2KDM4EGAA
SCHEMBL5668373 0.80 KMT2A (0.64) ALDH1A1KMT2ASMN1; SMN2KDM4EGAA
SCHEMBL27198359 0.80 KMT2A (0.64) ALDH1A1KMT2ASMN1; SMN2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109095-A1 METHOD FOR PREPARING OXIME DERIVATIVE SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-04-03 US disclosed
CN-114835660-B Preparation method of oxime ether 浙江理工大学 2024-03-22 CN disclosed
CN-114957123-B 3- (difluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof 浙江工业大学 2023-11-28 CN disclosed
CN-114957124-B 3- (trifluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof 浙江工业大学 2023-11-07 CN disclosed
WO-2023101319-A1 METHOD FOR PREPARING OXIME DERIVATIVE 서울대학교산학협력단 2023-06-08 WO disclosed
CN-114957123-A 3- (difluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof 浙江工业大学 2022-08-30 CN disclosed
CN-114957124-A 3- (trifluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof 浙江工业大学 2022-08-30 CN disclosed
CN-114835660-A Preparation method of oxime ether 浙江理工大学 2022-08-02 CN disclosed
EP-3012246-B1 POLYMORPHIC FORM OF N-[4-(TRIFLUOROMETHIL)BENZYL]-4-METHOXYBUTYRAMIDE LABORATORIO FARM C T S R L (IT) 2020-12-23 EP disclosed
CN-111978203-A Microwave synthesis method of benzaldehyde oxime compound 浙江工业大学 2020-11-24 CN disclosed
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2005-06-16 US disclosed
US-20050113440-A1 Compounds that modulate PPAR activity and methods for their preparation AUERBACH BRUCE J (US) 2005-05-26 US disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed
US-20030225158-A1 Compounds that modulate PPAR activity and methods for their preparation WARNER-LAMBERT COMPANY 2003-12-04 US disclosed
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2003-10-16 US disclosed
US-6376712-B2 REDUCTION OF THE CORRESPONDING OXIME COMPOUND CENTRAL GLASS COMPANY, LIMITED (JP) 2002-04-23 US disclosed
US-20020013500-A1 Process for producing trifluoromethylbenzylamines CENTRAL GLASS COMPANY, LIMITED (JP) 2002-01-31 US disclosed
US-6331649-B1 REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID CENTRAL GLASS COMPANY, LIMITED (JP) 2001-12-18 US disclosed
JP-2000273069-A PRODUCTION OF TRIFLUOROMETHYLBENZYLAMINE CENTRAL GLASS CO LTD 2000-10-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 LMNA 2902/4885ALDH1A1 269/4885CYP1A2 15/4885
US-20020013500-A1 Process for producing trifluoromethylbenzylamines MAOB, CYP2F1, AGL LMNA 4189/4885ALDH1A1 622/4885CYP1A2 25/4885
US-20030225158-A1 Compounds that modulate PPAR activity and methods for their preparation GPR119, PPARA, PPARG LMNA 1929/4885ALDH1A1 2456/4885CYP1A2 4202/4885
US-20050113440-A1 Compounds that modulate PPAR activity and methods for their preparation GPR119, PPARA, PPARG LMNA 1929/4885ALDH1A1 2456/4885CYP1A2 4202/4885
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 LMNA 4276/4885ALDH1A1 394/4885CYP1A2 420/4885
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 LMNA 4276/4885ALDH1A1 394/4885CYP1A2 420/4885
US-20250109095-A1 METHOD FOR PREPARING OXIME DERIVATIVE NOS2, NOS1, NOS3 LMNA 2671/4885ALDH1A1 1430/4885CYP1A2 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.